Roche
Perjeta becomes first approved drug for early breast cancer
October 1, 2013Sales and Marketing FDA, Herceptin, Perjeta, Roche
Roche’s Perjeta has become the first preoperative breast cancer drug to be authorised by the FDA after it was granted …
Eisai restates Halaven’s challenge to Roche’s Xeloda
September 30, 2013Research and Development, Sales and Marketing ECC, Halaven, Roche, Xeloda
Eisai has updated research on its breast cancer drug Halaven in a renewed bid to establish the treatment as a …
Roche cancer treatment shows promise
September 30, 2013Sales and Marketing MPDL3280A, Merck Serono, NSCLC, Roche
An early-stage oncology treatment has shown encouraging results in smokers with lung cancer, Roche has said in a presentation at …
Roche’s new Herceptin jab approved by NHS
September 25, 2013Sales and Marketing Herceptin, Kadcyla, Roche, breast cancer
CHMP recommends cancer ‘smart bomb’
September 23, 2013Research and Development, Sales and Marketing CHMP, Cancer, EMA, Kadcyla, Roche
Google launches new health business
September 19, 2013Medical Communications, Sales and Marketing Apple, Genentech, Levinson, Roche, google
FDA approves first generic Xeloda
September 17, 2013Sales and Marketing FDA, Roche, Teva, Xeolda, breast cancer, colorectal cancer
EFPIA slams EMA data proposals
September 10, 2013Research and Development, Sales and Marketing AZ, EFPIA, EMA, GSK, Pfizer, Roche
The intense debate over how pharma should make trial data available has taken another turn as a major European industry …
EU green light for ‘new’ Herceptin
September 3, 2013Sales and Marketing EU, Herceptin, Roche, breast cancer
Roche has ticked another approval off Herceptin’s list with the news that the European Commission is allowing a new form …
GSK and Roche get EU breast cancer indication
August 15, 2013Sales and Marketing GSK, Herceptin, Roche, Tyverb, Xeloda, breast cancer
The European Commission has granted a new indication for the use of GSK’s breast cancer drug Tyverb in combination with …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
